PAVmed (PAVM)
Building digital oncology, esophageal diagnostics, and medical-device platforms through a shared-services model.
Something off on this page? Send us feedback.
Develops and supports digital oncology, esophageal diagnostics, and medical-device businesses, earning reported revenue from Veris subscriptions while receiving Lucid management-service income. Its shared-services model spans separately financeable businesses, though Lucid is no longer consolidated.
Operates as a founder-led life-sciences holding and development company, centralizing management, finance, legal, regulatory, human-resources, sales, and marketing functions across separately financeable businesses. The portfolio includes Veris Health's Cancer Care Platform, a significant Lucid Diagnostics investment, and directly developed medical-device technologies.
Veris combines remote physiologic data, symptom reporting, telehealth, EHR integration, a patient app, clinician portal, and connected devices, producing subscription revenue from oncology deployments. The shared-services model also supplies Lucid with operating infrastructure, while PortIO and Duke-licensed endoscopic imaging remain in development.
Revenue and segment assets are concentrated in the United States. Lucid is not consolidated after PAVmed lost its controlling financial interest; its management-services agreement can be terminated by Lucid, while the active device portfolio remains subject to development, regulatory, manufacturing, reimbursement, and adoption steps.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $3.8M · Total debt $17.1M · Total assets $40.2M · Shareholders' equity $35.0M
- Revenue
- $33.0K
- Operating income
- −$7.0M
- Net income
- −$5.4M
No dividends on record.
| Institutions | 14.66% | 935.9K shares | |
|---|---|---|---|
| 19 holders · as of Jun 30, 2026 | |||
| Insiders | 35.09% | 2.24M shares | |
| 13 holders · as of Apr 13, 2026 | |||
| Strategic holders | 14.30% | 913.0K shares | |
| 1 holder · as of Apr 6, 2026 | |||
| Other | 35.95% | 2.29M shares | |
| remainder | |||
6.38M company shares as of Sep 14, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (8.00M in the company's Sep 23, 2026 report, 6.38M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Tasso Partners, LLCStrategic10 percent owner | 14.30% | 912,996 | filed Apr 6, 2026 |
Ayrton Capital LLCInstitution | 11.11% | 709,069 | filed May 11, 2026 |
Scopia Holdings LLCInstitution | 9.87% | 630,118 | filed Apr 13, 2026 |
Nagelberg David S.Insider | 8.57% | 546,964 | filed Apr 8, 2026 |
Two Seas Capital LPInstitution | 7.23% | 461,539 | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Health Catalyst
Oncology ePRO and EHR platform rival for cancer-center deployments.
- Guardant Health
Blood-based multi-cancer screening targets esophageal cancer detection.
- Abbott
Commercial multi-cancer blood testing versus esophageal cell screening.
- Teleflex
Incumbent intraosseous access system alongside a long-term implant path.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| PAVmed | $4.06 | −3.05% | $26.7M | — | — | 238.4 | +450.0% |
| Health Catalyst | $1.76 | −7.14% | $139.7M | — | — | 0.5 | −12.7% |
| Guardant Health | $176.53 | −0.36% | $23.77B | — | — | 20.1 | +44.3% |
| Abbott | $103.58 | −0.14% | $179.49B | 33.4 | 17.9 | 3.9 | +13.0% |
| Teleflex | $121.94 | −2.37% | $5.53B | — | 13.2 | 2.1 | −27.0% |
| Median | 33.4 | 15.5 | 3.0 | +0.2% |